Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Intellia Therapeutics ( (NTLA) ) just unveiled an update.
On May 18, 2025, Intellia Therapeutics announced positive two-year follow-up data from its ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). The study showed a significant reduction in serum TTR levels and clinically meaningful improvements in neuropathic impairment measures, with no serious adverse events, indicating potential for nex-z as a one-time treatment. The results were presented at the Peripheral Nerve Society Annual Meeting, highlighting the drug’s potential to improve outcomes for patients who previously showed disease progression on patisiran.
The most recent analyst rating on (NTLA) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.
Spark’s Take on NTLA Stock
According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.
The overall stock score for Intellia Therapeutics reflects a mixed yet promising outlook. The company’s strong clinical progress and regulatory milestones provide a positive sentiment, enhancing its future potential. However, current financial challenges, including declining revenues and net losses, weigh heavily on the score. The technical analysis indicates short-term momentum, but long-term trends suggest caution. The valuation remains challenging due to negative earnings, typical in the biotech sector.
To see Spark’s full report on NTLA stock, click here.
More about Intellia Therapeutics
Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on developing CRISPR-based therapies. The company is engaged in the development and commercialization of innovative treatments for hereditary transthyretin (ATTR) amyloidosis, among other conditions, through a collaboration with Regeneron Pharmaceuticals, Inc.
Average Trading Volume: 3,499,734
Technical Sentiment Signal: Sell
Current Market Cap: $880.5M
For detailed information about NTLA stock, go to TipRanks’ Stock Analysis page.